CANCER:

Germ Cell Tumors

News alerts, weekly reports and conference planners

No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	TI-CE Sensitive: A2 - Guideline TI-CE Sensitive : A2	TI-CE Sensitive: A2 - Guideline TI-CE Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	VC Sensitive: A2 - Guideline VC Sensitive : A2	VC Sensitive: A2 - Guideline VC Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	BEP Sensitive: A2 - Guideline BEP Sensitive : A2	BEP Sensitive: A2 - Guideline BEP Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	VIP Sensitive: A2 - Guideline VIP Sensitive : A2	VIP Sensitive: A2 - Guideline VIP Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	VAC Sensitive: A2 - Guideline VAC Sensitive : A2	VAC Sensitive: A2 - Guideline VAC Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	VeIP Sensitive: A2 - Guideline VeIP Sensitive : A2	VeIP Sensitive: A2 - Guideline VeIP Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	TIP Sensitive: A2 - Guideline TIP Sensitive : A2	TIP Sensitive: A2 - Guideline TIP Sensitive : A2
TMB-H	Germ Cell Tumors	TMB-H	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2	paclitaxel + gemcitabine Sensitive: A2 - Guideline paclitaxel + gemcitabine Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline paclitaxel + gemcitabine + oxaliplatin Sensitive : A2	paclitaxel + gemcitabine + oxaliplatin Sensitive: A2 - Guideline paclitaxel + gemcitabine + oxaliplatin Sensitive : A2
MSI-H/dMMR	Germ Cell Tumors	MSI-H/dMMR	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRCA1 mutation	Germ Cell Tumors	BRCA1 mutation	Germ Cell Tumors	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
XPA expression	Germ Cell Tumors	XPA expression	Germ Cell Tumors	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3
MTOR mutation	Germ Cell Tumors	MTOR mutation	Germ Cell Tumors	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
KRAS amplification	Germ Cell Tumors	KRAS amplification	Germ Cell Tumors	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3	MEK inhibitor Sensitive: C3 – Early Trials MEK inhibitor Sensitive : C3
Chr t(22)	Germ Cell Tumors	Chr t(22)	Germ Cell Tumors	cisplatin + ifosfamide + etoposide oral + mesna Sensitive: C4 – Case Studies cisplatin + ifosfamide + etoposide oral + mesna Sensitive : C4	cisplatin + ifosfamide + etoposide oral + mesna Sensitive: C4 – Case Studies cisplatin + ifosfamide + etoposide oral + mesna Sensitive : C4
EGFR L858R	Germ Cell Tumors	EGFR L858R	Germ Cell Tumors	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
BAX underexpression	Germ Cell Tumors	BAX underexpression	Germ Cell Tumors	cisplatin Resistant: C4 – Case Studies cisplatin Resistant : C4	cisplatin Resistant: C4 – Case Studies cisplatin Resistant : C4
TP53 mutation	Germ Cell Tumors	TP53 mutation	Germ Cell Tumors	cisplatin Resistant: C4 – Case Studies cisplatin Resistant : C4	cisplatin Resistant: C4 – Case Studies cisplatin Resistant : C4
EGFR L858R	Germ Cell Tumors	EGFR L858R	Germ Cell Tumors	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4	icotinib Sensitive: C4 – Case Studies icotinib Sensitive : C4
MSH6 mutation	Germ Cell Tumors	MSH6 mutation	Germ Cell Tumors	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4
BRCA2 mutation	Germ Cell Tumors	BRCA2 mutation	Germ Cell Tumors	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4

Germ Cell Tumors

Associations(36)

Associations
(36)